Intensity Therapeutics INTS
NASDAQ INTS
$3.28 -0.01 (-0.30%)
As of: Oct 20, 2026 · 3:59 PM EDT

Intensity Therapeutics (INTS) Non Operating Interest Expenses (2022 - 2023)

Updated

Intensity Therapeutics' Non Operating Interest Expenses was $305,000 in FY2023, up 272.0% from $82,000 in FY2022.

Analysis

Intensity Therapeutics (INTS) Non Operating Interest Expenses (2022 - 2023) Analysis & Trends

  • Per Business Quant data, Non Operating Interest Expenses in earlier years was $82,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn -
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 281.00 Mn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn -
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn -
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 435.00 Mn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 673.00 Mn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 247.00 Mn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn -
10 Intensity Therapeutics 8.93 Mn -29.83 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 222,000.00
Mar 31, 2023 83,000.00
Dec 31, 2022 37,123.00
Sep 30, 2022 15,123.00
Jun 30, 2022 14,959.00
API Access

Intensity Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=INTS&period=max&api_key=YOUR_API_KEY